Maher et al, confirmed in their molecular cell experiments that (41) (1-(4-iodophenyl)- 3 -(2-adamantyl) guanidine) (IPAG), an inhibitor of the endoplasmic reticulum molecular chaperone Sigma1, can inhibits the glycosylation modification of PD-L1 and reduces the binding ability of PD-L1 to PD-1, which promotes the killing of tumor cells by CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.